title: Src and focal adhesion kinase as therapeutic targets in cancer.
abstract: Over the past few years small molecule inhibitors of both Src family kinases and focal adhesion kinase (FAK) have entered clinical studies for the treatment of solid tumours. These adhesion-linked kinases are involved in a number of pathways that have impact on the behaviour of tumour cells and the challenge is now, how to take these forward in the clinical setting.
authors.affiliation: Institute of Genetics & Molecular Medicine, Division of Cancer Biology, University of Edinburgh, Crewe Road South, Edinburgh, United Kingdom. v.brunton@ed.ac.uk
authors.forename: Valerie G
authors.initials: VG
authors.lastname: Brunton
authors.forename: Margaret C
authors.initials: MC
authors.lastname: Frame
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D049109:Cell Proliferation / Q000187:drug effects; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects / Q000502:physiology; D019061:src-Family Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D051416:Focal Adhesion Protein-Tyrosine Kinases; D019061:src-Family Kinases